There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2


Brief Information

Target Synonym:T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IL2-H4113-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2, Tag Free (Cat. No. IL2-H4113) stimulates proliferation of CTLL-2 cells. The ED50 for this effect is 0.284-0.355 ng/ml (Routinely tested).


Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).


Loaded Biotinylated Human IL-2RB&IL-2RA&IL-2RG, Fc,Avitag&Fc,Avitag (Cat. No. ILG-H82F4) on SA Biosensor, can bind Human IL-2, His Tag (Cat. No. IL2-H52H8) with an affinity constant of 2.41 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

IL2,TCGF,lymphokine,Interleukin 2


Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Recombinant Human Interleukin-2 Injection (Beijing Four Rings Biopharmaceutical) Approved Beijing Four Rings Bio-Pharmaceutical Co Ltd 新德路生 Mainland China Thrombocytopenia Beijing Four Rings Bio-Pharmaceutical Co Ltd 1997-01-01 Thrombocytopenia Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Human interleukin-2 biosimilar (Amoytop Biotech/BioGeneric Pharma) rHuIL-2 Clinical Xiamen Amoytop Biotech Co Ltd, Biogeneric Carcinoma, Renal Cell; Melanoma Details
HBAI-20 HBAI-20; HBAI-20-CyTuVax Phase 2 Clinical Cytuvax Hepatitis B Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Atherosclerosis; Carcinoma, Basal Cell; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma Details
Autologous tumor cell vaccine (NCI) Phase 2 Clinical H Lee Moffitt Cancer Center & Research Institute, National Cancer Institute, Chiron Spa Carcinoma, Renal Cell; Melanoma Details
ITI-1000 ITI-1000 Phase 2 Clinical Immunomic Therapeutics Glioblastoma Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St. Jude Children'S Research Hospital, National Cancer Institute Neuroblastoma Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Melanoma Details
S-95007 S-95007 Phase 2 Clinical Servier Immune System Diseases; Inflammation Details
Interleukin-2 inhalation (Immunservice) Phase 3 Clinical Immunservice Carcinoma, Renal Cell Details
TG-4010 VV-MUC-IL2; TG-4010 Phase 2 Clinical Transgene Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
mRNA-6231 mRNA-6231 Phase 1 Clinical Moderna Therapeutics Autoimmune Diseases Details
SHR-1916 SHR-1916 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details

This web search service is supported by Google Inc.